On Demand 2018 Saturday General Sessions

This collection covers general sessions from Saturday's program. This includes plenaries, symposia, and workshops. The sessions listed below are included in this package:

  • Network Studies: Pulling it All Together for Adults and Kids
  • Advocacy Council Coding and Government Regulations Update
  • Best Current Treatment Options for Chronic Rhinosinusitis
  • Demystifying Oral Food Challenges in Infants and Toddlers
  • Expanding Our Role in the Community: Treating COPD in the Allergy/Immunology Practice Setting
  • ACAAI International Symposium: The Impact of the Environment on Allergic Disease
  • Going Nuts: The Complexities of Diagnosing and Managing Peanut and Tree Nut Allergy
  • Maximizing the Safe Delivery of Immunotherapy in the Office
  • Use of Genetic Testing for Diagnosis in Immunologic Disorders
  • Cannabis: What the Allergist Needs to Know About Marijuana: Medical and Recreational
  • Latest Issues & Controversies in Food Allergy
  • Lung Function Testing: Spirometry, FeNo, Challenges Done Right!

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 10 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Discuss how clinical trials on adult asthma produce information applicable to allergy/immunology practice.
  • Recognize how clinical trials on pediatric asthma produce information applicable to allergy/immunology practice.
  • Investigate ideas about how to encourage patients to collaborate with their caregivers when making decisions.
  • Identify changes that allergy practices will need to make if the currently-proposed USP and FDA regulations on mixing allergy extracts are finalized.
  • Utilize strategies for surviving and thriving in the face of changes in coding and governmental regulation.
  • Anticipate potential changes in 2019 driven by the recent elections that may impact allergy practices.
  • Discuss optimal management of chronic rhinosinusitis (CRS) in the era of biologics approved for severe asthma.
  • Recognize current best practices for standard of care for CRS with nasal polyps.
  • Identify elements of a patient’s clinical history and diagnostic testing which determine suitability for challenge.
  • Apply suggestions to make foods more palatable for infants.
  • Implement food challenges into practice through adoption of practical measures.
  • Identify COPD patients who may benefit from immunodeficiency treatment, perform immunodeficiency workups of these patients, and specify treatment plans for them.
  • Categorize the treatment of COPD patients in an allergy/ immunology practice setting.
  • Assess and implement tobacco-cessation strategies for patients in the allergy/immunology practice setting.
  • Understand the relationship between specific IgG4 and tolerance to allergens.
  • Describe the rationale for pursuing novel biologic targets for allergic diseases and asthma.
  • Understand how environmental exposures alter DNA and impact gene expression in allergic diseases and asthma.
  • Describe the utility of various diagnostic tests for nut allergies.
  • Discuss interpretation of test results given cross-reactivities and co-sensitizations.
  • Explain individualized management strategies to meet the needs and desires of patients and their families.
  • Review the literature regarding risk factors associated with immunotherapy.
  • Identify potential flaws in the system that may be associated with increased risk in giving immunotherapy.
  • Describe the role of genetic testing in the diagnosis of primary immune deficiency disorders.
  • Describe the medicinal effects and recognize adverse effects of marijuana.
  • Debate the health value and individual and societal costs of cannabis usage.
  • Apprise the patient of respiratory effects and allergic reactions to marijuana usage.
  • Discuss the risks, benefits and realistic expectations of food oral immunotherapy with parents and patients.
  • Apply an understanding of clinical history and negative/positive predictive values to the interpretation of food-specific IgE test results.
  • Communicate the lack of validity and clinical applicability of non-IgE testing in the evaluation of food allergy or sensitivity.
  • Identify the most recent resource and relevance of ATS/ERS guidelines for spirometry and Global Lung Initiative reference values for spirometry.
  • Apply updated 2017 ATS standards for performing acceptable, reproducible spirometry valid for interpretation.
  • Utilize the updated ATS guidelines to interpret spirometry and classify severity of identified abnormalities.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2018 Annual Meeting is now available online.

Course summary
Available credit: 
  • 19.00 AMA PRA Category 1 Credit™
  • 19.00 Attendance
  • 3.00 MOC
Course opens: 
12/01/2018
Course expires: 
11/30/2021
Cost:
$0.00
Rating: 
0

Cezmi A. Akdis, MD

Mubeccel Akdis, MD, PhD

Antoine E. Azar, MD

David I. Bernstein, MD, FACAAI

J. Andrew Bird, MD, FACAAI

 Hannelore A. Brucker, MD, FACAAI

Mario Castro, MD, MPH

Edmond S. Chan, MD

Carla M. Davis, MD, FACAAI

Tania Elliott, MD, FACAAI

Tolly E. Epstein, MD, MS, FACAAI

Ira Finegold, MD

David M. Fleischer, MD, FACAAI

Thomas A. Fleisher, MD, FACAAI

Matthew Greenhawt, MD, MSc, MBA, FACAAI

Justin C. Greiwe, MD, FACAAI

Gary N. Gross, MD, FACAAI

Stephen A. Imbeau, MD, FACAAI

Jayesh G. Kanuga, MD

Rohit K. Katial, MD, FACAAI

John M. Kelso, MD, FACAAI

Bryan L. Martin, DO, FACAAI

J. Allen Meadows, MD, FACAAI

Travis Miller, MD, FACAAI

David R. Naimi, DO

Anil Nanda, MD, FACAAI

Anna Nowak-Wegrzyn, MD

John J. Oppenheimer, MD, FACAAI

Purvi S. Parikh, MD

David B. Peden, MD, FACAAI

Benjamin Prince, MD, MSCI

Jennifer Puck, MD

Mamta Reddy, MD, FACAAI

Noel Rodriguez, MD, FACAAI

John R. Seyerle, MD, FACAAI

Naba A. Sharif, MD, FACAAI

William S. Silvers, MD, FACAAI

David R. Stukus, MD, FACAAI

James L. Sublett, MD, FACAAI

J. Wesley Sublett, MD, MPH, FACAAI

Mike Tankersley, MD, MBA, FACAAI

Stephen A. Tilles, MD, FACAAI

Troy Torgerson, MD, PhD

James M. Tracy, DO, FACAAI

Brian Vickery, MD

Available Credit

  • 19.00 AMA PRA Category 1 Credit™
  • 19.00 Attendance
  • 3.00 MOC

Accreditation Period

Course opens: 
12/01/2018
Course expires: 
11/30/2021

Price

Cost:
$0.00
Please login or create an account to take this course.